falsefalse

HER2 Alterations in Non-Small Cell Lung Cancer - Episode 3

Liquid vs Solid Tumor Biopsies in NSCLC

, , , ,

Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Biomarker Testing in NSCLC: Clinical Scenario
    EP. 2: Approaches to Biomarker Testing in NSCLC
    Now Viewing
    EP. 3: Liquid vs Solid Tumor Biopsies in NSCLC
    EP. 4: HER2 Alterations in NSCLC: Clinical Scenario
    EP. 5: The Role of HER2 Alterations in NSCLC
    EP. 6: Testing Patients with NSCLC for HER2 Mutations
    EP. 7: Current Treatment Options in NSCLC
    EP. 8: Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC
    EP. 9: HER2-Targeted Therapies in NSCLC
    EP. 10: Major Adverse Events of Anti-HER2 Therapies
    EP. 11: Unmet Needs in NSCLC Therapy
    EP. 12: Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC
    EP. 13: Novel HER2-Targeted Therapies for NSCLC

    Related Content:

    HER2 Alterations in Non-Small Cell Lung CancerLung CancerOncLive Peer Exchange®
    Zongertinib Could Alter SOC in HER2-Mutated Advanced NSCLC
    Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC
    Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial
    x